In an attempt to develop a treatment strategy to overcome the acquired EGFR C797S mutation, we recently showed that the EGFR C797S mutation is associated with the elevated expression of AXL, a receptor tyrosine kinase of the TAM (TYRO3-AXL-MER) family, and that the inhibition of AXL is effective in slowing the growth of NSCLC cells harboring EGFR C797S [7]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.